Esperion Therapeutics to Present at Stifel 2014 Healthcare Conference
Esperion Therapeutics to Present at Stifel 2014 Healthcare Conference
November 12, 2014
Presentation and Webcast on
A live, listen-only webcast of the presentation can be accessed on the investor relations section of the Esperion website at www.esperion.com. A webcast replay of the presentation will be available approximately one hour after completion and will be archived on the Company's website for 90 days following the event.
Esperion's Commitment to Cardiometabolic Disease
Esperion is committed to improving the lives of patients with cardiometabolic diseases. The Esperion team leverages its understanding of, and experience with, key biological pathways to discover and develop innovative therapies for the treatment of patients with hypercholesterolemia who have uncontrolled cholesterol levels despite the use of currently available therapies. Esperion has assembled a portfolio of programs including one product candidate in late-stage clinical evaluation (ETC-1002) and two pre-clinical product candidates.
About
Media Contact:
efox@w2ogroup.com
or
Investor
Contact:
mlowe@esperion.com
Source:
News Provided by Acquire Media